The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00732602

Enrollment

Registered

2008-08-12

Start date

2008-01-31

Completion date

Unknown

Last updated

2009-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

Glucagon, Glucose-dependent Insulinotropic Polypeptide, Glucagon-Like peptide 2

Brief summary

The purpose of this study is to determine whether Glucose-dependent Insulinotropic Polypeptide (GIP) or Glucagon Like Peptide 2 (GLP-2) has an affect on the secretion of Glucagon from the pancreas in patients with type 1 diabetes mellitus.

Interventions

OTHERGIP-infusion

OTHERSodium-chloride

OTHERGLP-2 infusion

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Caucasians over 18 years with type 1 diabetes (WHO criteria) * Arginine test without rise in plasma C-peptide * Normal blood Hemoglobin * Informed consent

Exclusion criteria

* Liver disease * Diabetic nephropathy * Treatment with medications unpausable for 12 hours

Design outcomes

Primary

Measure	Time frame
plasma-glucagon Area Under Curve at 0-90 min. and 90-180 min.	—

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026